Cellworks Omics Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance.

Paclitaxel and carboplatin (PC) is used to treat a wide variety of malignancies including gynecologic, breast, lung, and occult primary cancers. In NSCLC, PC led to a substantial improvement in 1-yr survival from 10% (P alone) to approximately 50% seen with the combination.